Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
377
Employees377
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
377
Employees377

NTLA Key Statistics

Market cap
1.79B
Market cap1.79B
Price-Earnings ratio
-3.80
Price-Earnings ratio-3.80
Dividend yield
Dividend yield
Average volume
3.00M
Average volume3.00M
High today
$12.96
High today$12.96
Low today
$12.52
Low today$12.52
Open price
$12.57
Open price$12.57
Volume
2.80M
Volume2.80M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$7.95
52 Week low$7.95

Stock Snapshot

As of today, Intellia Therapeutics(NTLA) shares are valued at $12.84. The company's market cap stands at 1.79B, with a P/E ratio of -3.80.

During the trading session on 2026-09-06, Intellia Therapeutics(NTLA) shares reached a daily high of $12.96 and a low of $12.52. At a current price of $12.84, the stock is +2.6% higher than the low and still -0.9% under the high.

Trading volume for Intellia Therapeutics(NTLA) stock has reached 2.8M, versus its average volume of 3M.

The stock's 52-week range extends from a low of $7.95 to a high of $28.25.

The stock's 52-week range extends from a low of $7.95 to a high of $28.25.

NTLA News

TipRanks 2d
Intellia Therapeutics Secures Major Non-Dilutive Loan Financing

Intellia Therapeutics ( (NTLA) ) has provided an announcement. On September 4, 2026, Intellia Therapeutics entered into a five-year non-dilutive senior secured...

Simply Wall St 2d
Intellia Therapeutics Stock Could Be Fully Priced On Pipeline Hopes

Intellia Therapeutics stock has had a difficult longer term run, with the share price down about 92.1% over the past five years. However, recent gains and curre...

Intellia Therapeutics Stock Could Be Fully Priced On Pipeline Hopes
TipRanks 4d
Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today

20:25 EDT Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time, m...

Analyst ratings

53%

of 19 ratings
Buy
52.6%
Hold
31.6%
Sell
15.8%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.